Mesenchymal stromal cells (MSCs) are applied as novel therapeutics for their regenerative and immune-suppressive capacities. Clinical applications, however, require extensive expansion of MSCs. Fetal bone marrow-derived MSCs (FBMSCs) proliferate faster than adult bone marrow-derived MSC (ABMSCs). To optimize expansion and function of MSC in general, we explored the differences between ABMSC and FBMSC. Gene expression profiling implicated differential expression of genes encoding proteins in the Wnt signaling pathway, including excreted inhibitors of Wnt signaling, particularly by ABMSC. Both MSC types had a similar basal level of canonical Wnt signaling. Abrogation of autocrine Wnt production by inhibitor of Wnt production-2 (IWP2) reduced canonical Wnt signaling and cell proliferation of FBMSCs, but hardly affected ABMSC. Addition of exogenous Wnt3a, however, induced expression of the target genes lymphocyte enhancer-binding factor (LEF) and T-cell factor (TCF) faster and at lower Wnt3a levels in ABMSC compared to FBMSC. Medium replacement experiments indicated that ABMSC produce an inhibitor of Wnt signaling that is effective on ABMSC itself but not on FBMSC, whereas FBMSC excrete (Wnt) factors that stimulate proliferation of ABMSC. In contrast, FBMSC were not able to support hematopoiesis, whereas ABMSC displayed hematopoietic support sensitive to IWP2, the inhibitor of Wnt factor excretion. In conclusion, ABMSC and FBMSC differ in their Wnt signature. While FBMSC produced factors, including Wnt signals, that enhanced MSC proliferation, ABMSC produced Wnt factors in a setting that enhanced hematopoietic support. Thus, further unraveling the molecular basis of this phenomenon may lead to improvement of clinical expansion protocols of ABMSCs.
Get full access to this article
View all access options for this article.
References
1.
CampagnoliC, RobertsIA, KumarS, BennettPR, BellantuonoI and FiskNM. (2001). Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood, 98:2396–2402.
2.
da Silva MeirellesL, ChagastellesPC and NardiNB. (2006). Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci, 119:2204–2213.
3.
FanCG, TangFW, ZhangQJ, LuSH, LiuHY, ZhaoZM, LiuB, HanZB and HanZC. (2005). Characterization and neural differentiation of fetal lung mesenchymal stem cells. Cell Transplant, 14:311–321.
4.
in‘t AnkerPS, NoortWA, ScherjonSA, Kleijburg-van der KeurC, KruisselbrinkAB, van BezooijenRL, BeekhuizenW, WillemzeR, KanhaiHH and FibbeWE. (2003). Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica, 88:845–852.
5.
Le BlancK, GotherstromC, RingdenO, HassanM, McMahonR, HorwitzE, AnnerenG, AxelssonO, NunnJ, et al. (2005). Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation, 79:1607–1614.
6.
CaplanAI. (1994). The mesengenic process. Clin Plast Surg, 21:429–435.
7.
O'DonoghueK and FiskNM. (2004). Fetal stem cells. Best Pract Res Clin Obstet Gynaecol, 18:853–875.
8.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniF, KrauseD, DeansR, KeatingA, ProckopD and HorwitzE. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
9.
MaijenburgMW, GilissenC, MeliefSM, KleijerM, WeijerK, Ten BrinkeA, RoelofsH, Van TielCM, VeltmanJA, et al. (2012). Nuclear receptors Nur77 and Nurr1 modulate mesenchymal stromal cell migration. Stem Cells Dev, 21:228–238.
10.
RoelenDL, van der MastBJ, in't AnkerPS, KleijburgC, EikmansM, van BeelenE, de Groot-SwingsGM, FibbeWE, KanhaiHH, ScherjonSA and ClaasFH. (2009). Differential immunomodulatory effects of fetal versus maternal multipotent stromal cells. Hum Immunol, 70:16–23.
11.
CharbordP, TavianM, HumeauL and PeaultB. (1996). Early ontogeny of the human marrow from long bones: an immunohistochemical study of hematopoiesis and its microenvironment. Blood, 87:4109–4119.
12.
CharbordP, OostendorpR, PangW, HeraultO, NoelF, TsujiT, DzierzakE and PeaultB. (2002). Comparative study of stromal cell lines derived from embryonic, fetal, and postnatal mouse blood-forming tissues. Exp Hematol, 30:1202–1210.
13.
LoganCY and NusseR. (2004). The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol, 20:781–810.
14.
MurdochB, ChadwickK, MartinM, ShojaeiF, ShahKV, GallacherL, MoonRT and BhatiaM. (2003). Wnt-5A augments repopulating capacity and primitive hematopoietic development of human blood stem cells in vivo. Proc Natl Acad Sci U S A, 100:3422–3427.
15.
MinearS, LeuchtP, JiangJ, LiuB, ZengA, FuererC, NusseR and HelmsJA. (2010). Wnt proteins promote bone regeneration. Sci Transl Med, 2:29ra30.
16.
BakshD, BolandGM and TuanRS. (2007). Cross-talk between Wnt signaling pathways in human mesenchymal stem cells leads to functional antagonism during osteogenic differentiation. J Cell Biochem, 101:1109–1124.
17.
BilkovskiR, SchulteDM, OberhauserF, GomolkaM, UdelhovenM, HettichMM, RothB, HeidenreichA, GutschowC, KroneW and LaudesM. (2010). Role of WNT-5a in the determination of human mesenchymal stem cells into preadipocytes. J Biol Chem, 285:6170–6178.
18.
GaurT, RichL, LengnerCJ, HussainS, TrevantB, AyersD, SteinJL, BodinePV, KommBS, SteinGS and LianJB. (2006). Secreted frizzled related protein 1 regulates Wnt signaling for BMP2 induced chondrocyte differentiation. J Cell Physiol, 208:87–96.
19.
BolandGM, PerkinsG, HallDJ and TuanRS. (2004). Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J Cell Biochem, 93:1210–1230.
20.
GregoryCA, SinghH, PerryAS and ProckopDJ. (2003). The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow. J Biol Chem, 278:28067–28078.
21.
CongdonKL, VoermansC, FergusonEC, DiMascioLN, UqoezwaM, ZhaoC and ReyaT. (2008). Activation of Wnt signaling in hematopoietic regeneration. Stem Cells, 26:1202–1210.
22.
LentoW, CongdonK, VoermansC, KritzikM and ReyaT. (2013). Wnt signaling in normal and malignant hematopoiesis. Cold Spring Harb Perspect Biol, 5:pii: a008011.
23.
OhIH. (2010). Microenvironmental targeting of Wnt/beta-catenin signals for hematopoietic stem cell regulation. Expert Opin Biol Ther, 10:1315–1329.
24.
van AmerongenR and NusseR. (2009). Towards an integrated view of Wnt signaling in development. Development, 136:3205–3214.
25.
CarmonKS, LinQ, GongX, ThomasA and LiuQ. (2012). LGR5 interacts and cointernalizes with Wnt receptors to modulate Wnt/beta-catenin signaling. Mol Cell Biol, 32:2054–2064.
26.
CarmonKS, GongX, LinQ, ThomasA and LiuQ. (2011). R-spondins function as ligands of the orphan receptors LGR4 and LGR5 to regulate Wnt/beta-catenin signaling. Proc Natl Acad Sci U S A, 108:11452–11457.
27.
TaoQ, YokotaC, PuckH, KofronM, BirsoyB, YanD, AsashimaM, WylieCC, LinX and HeasmanJ. (2005). Maternal wnt11 activates the canonical wnt signaling pathway required for axis formation in Xenopus embryos. Cell, 120:857–871.
28.
CruciatCM and NiehrsC. (2013). Secreted and transmembrane wnt inhibitors and activators. Cold Spring Harb Perspect Biol, 5:a015081.
29.
PlanutisK, PlanutieneM and HolcombeRF. (2014). A novel signaling pathway regulates colon cancer angiogenesis through Norrin. Sci Rep, 4:5630.
30.
RuffnerH, SprungerJ, CharlatO, Leighton-DaviesJ, GrosshansB, SalatheA, ZietzlingS, BeckV, TherierM, et al. (2012). R-Spondin potentiates Wnt/beta-catenin signaling through orphan receptors LGR4 and LGR5. PLoS One, 7:e40976.
31.
KimJA, KangYJ, ParkG, KimM, ParkYO, KimH, LeemSH, ChuIS, LeeJS, JhoEH and OhIH. (2009). Identification of a stroma-mediated Wnt/beta-catenin signal promoting self-renewal of hematopoietic stem cells in the stem cell niche. Stem Cells, 27:1318–1329.
32.
NemethMJ, MakKK, YangY and BodineDM. (2009). beta-Catenin expression in the bone marrow microenvironment is required for long-term maintenance of primitive hematopoietic cells. Stem Cells, 27:1109–1119.
33.
EtheridgeSL, SpencerGJ, HeathDJ and GeneverPG. (2004). Expression profiling and functional analysis of wnt signaling mechanisms in mesenchymal stem cells. Stem Cells, 22:849–860.
34.
KlamerSE, KuijkCG, HordijkPL, van der SchootCE, von LindernM, van HennikPB and VoermansC. (2013). BIGH3 modulates adhesion and migration of hematopoietic stem and progenitor cells. Cell Adh Migr, 7:434–449.
35.
ChenB, DodgeME, TangW, LuJ, MaZ, FanCW, WeiS, HaoW, KilgoreJ, et al. (2009). Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol, 5:100–107.
36.
FuererC and NusseR. (2010). Lentiviral vectors to probe and manipulate the Wnt signaling pathway. PLoS One, 5:e9370.
37.
MaijenburgMW, NoortWA, KleijerM, KompierCJ, WeijerK, van BuulJD, van der SchootCE and VoermansC. (2010). Cell cycle and tissue of origin contribute to the migratory behaviour of human fetal and adult mesenchymal stromal cells. Br J Haematol, 148:428–440.
38.
MaijenburgMW, GilissenC, MeliefSM, KleijerM, WeijerK, Ten BrinkeA, RoelofsH, Van TielCM, VeltmanJA, et al. (2012). Nuclear receptors Nur77 and Nurr1 modulate mesenchymal stromal cell migration. Stem Cells Dev, 21:228–238.
39.
GuillotPV, GotherstromC, ChanJ, KurataH and FiskNM. (2007). Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC. Stem Cells, 25:646–654.
40.
BovolentaP, EsteveP, RuizJM, CisnerosE and Lopez-RiosJ. (2008). Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease. J Cell Sci, 121:737–746.
41.
GregoryMA, PhangTL, NevianiP, Alvarez-CalderonF, EideCA, O'HareT, ZaberezhnyyV, WilliamsRT, DrukerBJ, PerrottiD and DegregoriJ. (2010). Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell, 18:74–87.
42.
MalhotraS and KincadePW. (2009). Wnt-related molecules and signaling pathway equilibrium in hematopoiesis. Cell Stem Cell, 4:27–36.
43.
ZhangZY, TeohSH, ChongMS, SchantzJT, FiskNM, ChoolaniMA and ChanJ. (2009). Superior osteogenic capacity for bone tissue engineering of fetal compared with perinatal and adult mesenchymal stem cells. Stem Cells, 27:126–137.
44.
GotherstromC, WestA, LidenJ, UzunelM, LahesmaaR and Le BlancK. (2005). Difference in gene expression between human fetal liver and adult bone marrow mesenchymal stem cells. Haematologica, 90:1017–1026.
45.
TakashimaY, EraT, NakaoK, KondoS, KasugaM, SmithAG and NishikawaS. (2007). Neuroepithelial cells supply an initial transient wave of MSC differentiation. Cell, 129:1377–1388.
46.
MaijenburgMW, KleijerM, VermeulK, MulEP, van AlphenFP, van der SchootCE and VoermansC. (2012). The composition of the mesenchymal stromal cell compartment in human bone marrow changes during development and aging. Haematologica, 97:179–183.
47.
TorminA, LiO, BruneJC, WalshS, SchutzB, EhingerM, DitzelN, KassemM and SchedingS. (2011). CD146 expression on primary nonhematopoietic bone marrow stem cells is correlated with in situ localization. Blood, 117:5067–5077.
48.
BakshD and TuanRS. (2007). Canonical and non-canonical Wnts differentially affect the development potential of primary isolate of human bone marrow mesenchymal stem cells. J Cell Physiol, 212:817–826.
49.
WuX, TuX, JoengKS, HiltonMJ, WilliamsDA and LongF. (2008). Rac1 activation controls nuclear localization of beta-catenin during canonical Wnt signaling. Cell, 133:340–353.
50.
SatoA, YamamotoH, SakaneH, KoyamaH and KikuchiA. (2010). Wnt5a regulates distinct signalling pathways by binding to Frizzled2. EMBO J, 29:41–54.
51.
WoudaRR, BansrajMR, de JongAW, NoordermeerJN and FradkinLG. (2008). Src family kinases are required for WNT5 signaling through the Derailed/RYK receptor in the Drosophila embryonic central nervous system. Development, 135:2277–2287.
52.
ZhangL and WranaJL. (2014). The emerging role of exosomes in Wnt secretion and transport. Curr Opin Genet Dev, 27:14–19.
53.
FlemingHE, JanzenV, Lo CelsoC, GuoJ, LeahyKM, KronenbergHM and ScaddenDT. (2008). Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. Cell Stem Cell, 2:274–283.
54.
RenstromJ, IstvanffyR, GauthierK, ShimonoA, MagesJ, Jardon-AlvarezA, KrogerM, SchiemannM, BuschDH, et al. (2009). Secreted frizzled-related protein 1 extrinsically regulates cycling activity and maintenance of hematopoietic stem cells. Cell Stem Cell, 5:157–167.
55.
LuisTC, IchiiM, BrugmanMH, KincadeP and StaalFJ. (2012). Wnt signaling strength regulates normal hematopoiesis and its deregulation is involved in leukemia development. Leukemia, 26:414–421.
56.
NgCP, SharifAR, HeathDE, ChowJW, ZhangCB, Chan-ParkMB, HammondPT, ChanJK and GriffithLG. (2014). Enhanced ex vivo expansion of adult mesenchymal stem cells by fetal mesenchymal stem cell ECM1. Biomaterials, 35:4046–4057.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
